ScopeBio raises investment for smart DNA CRISPR tests
Scope Biosciences has secured a new investment.
Published on June 16, 2025
Team IO+ selects and features the most important news stories on innovation and technology, carefully curated by our editors.
Scope Biosciences , a spin-off from Wageningen University & Research, has secured an investment from SHIFT Invest and Oost NL. The funding follows on the company’s strong progression and first significant commercial traction.
ScopeBio’s mission centers on scopeDx®, a CRISPR-based diagnostic platform that can detect even the tiniest changes in DNA. It’s ultra-precise, portable, and works without the need for special equipment or a lab.
Agriculture and healthcare
The technology allows diagnostics to be performed closer to the source — in the field, at the point of care, or directly within agricultural operations. In agriculture, this enables earlier and more effective detection of crop diseases, helping to reduce losses and improve yields. In healthcare, it contributes to faster and broader access to reliable testing, especially in areas where centralized laboratories are not available.
'Ready for the real world'
“We’re grateful for the continued backing of SHIFT and Oost NL, and proud to have secured significant public and private support as we bring our technology closer to market,” said Niek Savelkoul, CEO and founder of ScopeBio. “We’re scaling up, building out our platform, and getting ready to meet real-world diagnostic challenges head-on.”
Including this new capital, together with a previously awarded €2.5 million EIC Transition Grant and earlier investments, ScopeBio has now secured a total of €6 million in seed-stage funding.
